Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Beats Sanofi On Lantus Patent

Company Ready To Launch Insulin Glargine Upon FDA Approval

Executive Summary

A US district court has ruled in favor of Mylan in a dispute with Sanofi over a Lantus SoloStar device patent, with the patent protecting the insulin glargine injector pen found to be invalid and not infringed. Mylan, along with partner Biocon, expects to launch its Semglee version mid-year, following FDA approval.

You may also be interested in...



US Court Rules In Favor Of Viatris For Interchangeable Semglee

Viatris and Biocon continue marketing their recently launched interchangeable biosimilar Semglee (insulin glargine-yfgn) as a US appeals court affirms that the challenged claims of five of Sanofi’s Lantus SoloSTAR device patents are unpatentable.

Mylan And Biocon’s Semglee Insulin Glargine Approved In US

Mylan and Biocon have received FDA approval for their Semglee insulin glargine product, with a path to market seemingly clear after Mylan emerged victorious in several recent patent-litigation challenges. Meanwhile, the firm continues to strive towards an interchangeability designation that would make it a much more valuable opportunity.

Mylan Prepares To Launch Insulin Glargine After Another Lantus IP Win

Mylan says it is now ready to launch its Semglee insulin glargine rival to Sanofi’s Lantus in the US upon FDA approval, after removing the final intellectual-property barriers by way of a favorable inter partes review decision.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel